- Research article
- Open Access
Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells
BMC Pharmacology volume 8, Article number: 9 (2008)
The H3 histamine receptor is a Gi-coupled GPCR that has been proven to exist in different agonist-induced states, including that defined by the protean agonist proxyfan. Several GPCRs are now known to exist in different states. For some of these, antagonist affinity measurement remain constant regardless of the state of the receptor, for others e.g. the beta-adrenoceptors, the antagonist affinity measurements vary considerably depending on which agonist-dependent state is being identified. The purpose of this study was to examine the antagonist affinity measurements at the Gi-coupling human H3 receptor, paying particular attention to measurements made in the presence of full agonists, partial agonists and the proxyfan protean agonist-induced state of the receptor.
CHO cells stably expressing the human histamine H3 receptor and a CRE-SPAP reporter were used. Measurements of CRE-gene transcription and 3H-cAMP accumulation were made. A range of ligands of different agonist efficacies were determined, including some partial agonists e.g. VUF 5681. Unlike other Gi-coupled receptors, no Gs-coupled state of the receptor was detected with these ligands. Antagonist affinity measurements were constant, whether the measurements were made in the presence of a full agonist, a partial agonist or the protean agonist proxyfan.
In contrast to all three subtypes of the beta-adrenoceptors, but in keeping with the traditional pharmacological dogma, antagonist affinity measurements remained constant at the human H3 receptor, including the medium-efficacy proxyfan-induced state of the receptor and the VUF5681-induced state of the receptor.
Antagonist affinity measurements have always played a key role in pharmacology [1–3]. They have been vital in the initial determination of different receptor sub-types and have been a major tool in determining which receptor subtypes are present within a given tissue (e.g. [1, 4, 5]. But these definitions have been made on the assumption that antagonist affinity measurements remain stable for a given ligand-receptor interaction, regardless of the competing agonist or the assay used to determine it.
Recently it has been shown that antagonist affinity measurements do not remain constant at the β-adrenoceptors [6–8]. Antagonist affinity measurements at the human β1-adrenoceptor may vary up to 3000 fold within the same experimental set up purely depending on which ligand is the competing agonist (e.g. [9–13]). Initially this led to the suggestion of the existence of a β4-adrenoceptor, however many studies since, including those using knockout animals [14, 15], have shown that the different antagonist affinities determined are from one receptor, the β1-adrenoceptor, but that this receptor exists in at least two different agonist states [6–8].
Several GPCRs have now been shown to exist in more that one agonist state or conformation.
For some receptors, this results in signalling via more than one class of G-protein (e.g. [16–18]. For other GPCRs, the different agonist-induced states of the receptor have different abilities to bind antagonists, e.g. β1 and β3-adrenoceptors [12, 19]. The human β2-adrenoceptor also appears to exist in at least two-agonist induced states, for which antagonist affinity measurements vary in CRE-gene transcription assays. However the reason for this remains unclear but may result from a time-dependent efficacy-related process . Some GPCRs appear to differentially activate different signalling cascades and must also exist in different states [21–24]. Finally studies to date with other GCPRs do not detect the existence of any other state (at least with the ligands currently available) and are therefore considered to exist in a single agonist conformation with a constant antagonist affinity .
The histamine H3 receptor is a constitutively active GPCR that is involved in neurotransmitter release within the CNS  and references therein. The histamine receptor subtypes H1 and H2 were first characterised in the 1960's and 1970's [2, 5]. Then in the 1970's and early 1980's, Arrang, Schwartz and colleagues observed that not all histamine actions in rat neurones were inhibited by H1 and H2 antagonists in a manner that fitted the profile for either histamine receptor subtype and therefore proposed a third histamine receptor subtype [26, 27]. The existence of the histamine H3 receptor was finally confirmed by the demonstration that R-α-methylhistamine was more potent than S-α-methylhistamine in reducing histamine release from rat brain slices and the identification of thioperamide as a selective H3 antagonist . The H3 receptor was cloned in 1999  and many selective and very high potency H3 agonists and antagonists have been identified . The H3 receptor couples to heterotrimeric Gi/o-proteins, activation of which causes a decrease in cAMP production and PKA activation . Its other known actions (including activation of phospholipase A2, Akt/GSK-3β axis and MAPK pathways, inhibition of the Na+/H+ exchanger and modulation of intracellular calcium) are all thought to occur via the various subunits of the heterotrimeric G-protein following Gi/o activation .
Recently, several unusual properties for the histamine H3 receptor and its ligands have been demonstrated. Of particularly interest here is that the H3 receptor exists in different agonist-induced states. Proxyfan has been demonstrated to be a protean agonist  of the H3 receptor – thus the efficacy observed depends upon the receptor expression level and constitutive activity in the system under study . Proxyfan stabilises a medium-efficacy state of the H3 receptor and so appears as a full or partial agonist in systems with less constitutive activity, a neutral antagonist of higher efficacy ligands in lower receptor expression systems, and an inverse agonist in highly constitutively active system, where it stabilises a receptor conformation of lower efficacy than the constitutively active state . Thus proxyfan has conclusively demonstrated that the histamine H3 receptor exists in more than one agonist state or conformation.
The aim of this study was therefore to examine the antagonist affinity measurements made at the human H3 histamine receptor stably expressed in CHO cells using a CRE-reporter gene system. This study examines, in detail, antagonist affinity measurements made at the different states of the H3 receptor including those induced by partial agonists, and at the medium-efficacy proxyfan induced state as distinct from the full-agonist histamine induced state of the receptor.
Fetal calf serum was from PAA laboratories (Teddington, Middlesex, UK). 3H-adenine and 14C-cAMP were from Amersham International (Buckinghamshire, UK). N-α-methylhistamine, R-α-methylhistamine, S-α-methylhistamine, 4-methylhistamine, immepip, imetit, immethridine, impentamine, amthamine, dimaprit, VUF 5681, VUF 8430, HTMT, 2-pyridylethylamine, iodophenpropit, clobenpropit, proxyfan, zolatidine, conessine, thioperamide, dimethindene, triprolidine, clemastine and burimamide were obtained from Tocris Cookson (Avonmounth, Bristol, UK). Pertussin toxin was from Calbiochem (Nottingham, UK). Histamine, cimetidine, ranitidine, 1-methylhistamine, 3-methylhistamine, chlorpheniramine, IBMX and forskolin were from Sigma Chemicals (Poole, Dorset, UK) who also supplied all other reagents.
A stable clonal CHO-K1 cell line expressing a CRE-SPAP reporter gene (six CRE upstream of a SPAP reporter) was secondarily transfected with the full length human histamine H3 receptor (DNA from DNA from UMR cDNA Resource Centre) using Lipofectamine and OPTIMEM as per manufacturer's instructions. The transfected cells were selected for neomycin resistance (1 mg/ml; for H3 receptor) and hygromycin resistance (200 μg/ml; for CRE-SPAP reporter gene) for 3 weeks and passaged twice during in this period. A single clone was then isolated by dilution cloning to give a clonal line (CHO-H3-SPAP cells). The parent cell CRE-SPAP was also used for control experiments (CHO-SPAP cells). Cells were grown in Dulbecco's modified Eagles medium/Nutrient mix F12 (DMEM/F12) containing 10% fetal calf serum and 2 mM L-glutamine at 37°C in a humidified 5% CO2: 95% air atmosphere.
3H-R-α-methylhistamine whole cell binding
Cells were grown to confluence in white-sided 96-well view plates. The media was then removed and replaced with 100 μl ice cold PBS (4°C) per well (total binding) or 100 μl ice cold PBS (4°C) containing 1 μM iodophenpropit (non-specific binding). 100 μl 3H-R-α-methylhistamine was then immediately added to the wells to give concentrations in the range of 0.024–224 nM. Cells were then maintained a 4°C for 5 hours. All PBS and drugs were removed and the cells washed twice by the addition and removal of 2 × 200 μl 4°C PBS. A white bottom and clear sealant top was added to the wells, the plates left overnight in the dark at room temperature and the plates counted on a Topcount (Packard) at 21°C 2 minute count per well.
CRE-SPAP gene transcription
Cells were grown to confluence in 96-well tissue culture plates. The cells were then serum starved by removing the media and replacing it with 100 μl serum free media (DMEM/F12 containing 2 mM L-glutamine). The cells were then incubated for a further 24 hours (humidified 5% CO2: 95% air atmosphere at 37°C). Where used, pertussis toxin, at a final concentration of 100 ng/ml was added to the serum-free media and thus incubated with the cells for 24 hours. On the day of experimentation, the serum-free media was removed and replaced with 100 μl serum-free media or 100 μl serum-free media containing an antagonist at the final required concentration and the cells incubated for 1 hour. Agonist in 10 μl (diluted in serum free media) was then added to each well and the cells incubated for 10 minutes. Forskolin was then added to all but the basal wells to give a final well concentration of 4 μM and the plates incubated for 5 hours. After 5 hours, the media and all drugs were removed. 40 μl serum-free media was added to each well and the cells incubated for a further 1 hour (37°C, 5% CO2: 95% air atmosphere). The plates were then incubated at 65°C for 30 minutes to destroy any endogenous phosphatases. After cooling to 37°C, 100 μl 5 mM pNPP in diethanolamine buffer was added to each well and the plates incubated at 37°C in a normal atmosphere until the yellow colour developed. The plates were then read on a Dynatech MRX plate reader at 405 nm.
Cells were grown to confluence in 24-well plates. The media was removed and the cells pre-labelled with 3H-adenine by incubation with 2 μCi/ml 3H-adenine in serum-free media (0.5 ml per well) for 3 hours. The 3H-adenine was then removed and the cells washed by the addition then removal of 1 ml serum-free media. 1 ml serum-free media containing 100 μM IBMX with or without the final required concentration of antagonist was then added to each well and the cells incubated for 30 minutes. Agonist (in 10 μl serum-free media) was added to each well and the plates incubated for 10 minutes. Forskolin (final concentration of 10 μM) was then added to all but the basal wells and the plates incubated for 30 minutes. The reaction was terminated by the addition of 50 μl concentrated HCl per well and the plates were then frozen. Later, the plates were thawed and 3H-cAMP separated from other 3H-nucleotides by sequential Dowex and alumina column chromatography, as previously described .
When the intrinsic efficacy of the antagonist ligands was examined, the antagonists were incubated for 5 hours at 37°C in order to maximise the chance of detecting any changes in 3H-cAMP accumulation.
To determine the expression level in the CHO-H3-SPAP cells, the saturation curves for specific 3H-R-α-methylhistamine binding were fitted to the following equation using GraphPad Prism 2:
However, as the specific binding curves appeared to contain a linear component, the data were also fitted to the following expression:
Bmax is the maximum specific binding, KD is the dissociation constant of 3H-R-α-methylhistamine, [3H-Rαmh] is the concentration of 3H-R-α-methylhistamine and M is the slop of the linear component of binding.
Sigmoidal concentration-response curves were fitted to the data using Graphpad Prism 2 and the following equation:
where Emax is the maximal response, [A] is the agonist concentration and IC50 is the concentration of agonist that produces 50% of the maximal response.
Antagonist KD values were then calculated from the shift of the agonist concentration responses in the presence of a fixed concentration of antagonist using the following equation:
where DR (dose ratio) is the ratio of the agonist concentration required to stimulate an identical response in the presence and absence of a fixed concentration of antagonist [B].
In experiments where three different fixed concentrations of the same antagonist were used, Schild plots were constructed using the following equation:
These points were then fitted to a straight line. A slope of 1 then indicates competitive antagonism .
When VUF 5681 was used as an antagonist (e.g. Figure 4), the partial agonist nature of this ligand was seen. Partial agonist dissociation constants were therefore estimated according to the method of Stephenson  using the following equation:
where [P] in the concentration of the partial agonist VUF 5681, [A1] in the concentration of the agonist at the point where the fixed partial agonist causes the same response, [A2] in the concentration of agonist causing a given response above that achieved by the partial agonist and [A3] the concentration of the agonist, in the presence of the partial agonist, causing the same stimulation as [A2].
In Figure 6a, the concentration-response curve is best fitted to a 2-component response, the following equation was used:
where N is the percentage of site 1, [A] is the concentration of agonist and IC150 and IC250 are the respective IC50 values for the two agonist sites.
All data are presented as mean ± s.e.m. of triplicate determinations where n is the number of separate experiments.
Determination of CHO-H3-SPAP cell line H3-receptor expression level
From the saturation binding studies, the KD value for 3H-R-α-methylhistamine was 4.10 ± 0.62 nM (n = 7). The receptor expression level of the human H3 receptor as determined by 3H-R-α-methylhistamine was 72.6 ± 8.0 fmol/mg protein (n = 7).
Identification of H3 agonists
Histamine agonists were first screened for inhibition of forskolin-stimulated CRE-SPAP production in CHO-H3-SPAP cells. In addition to the many ligands traditionally considered to be H3 agonists, several others were found to have partial agonist actions – e.g. burimamide and impentamine in keeping with previous studies (Figure 1a, Table 1). VUF 5681 was found to also have agonist properties. In addition the H2 agonists amthamine and dimaprit stimulated agonist responses (pIC50 = 4.87 ± 0.08, n = 3; pIC50 = 5.59 ± 0.18, n = 6, respectively) as well as HTMT (an H2-agonist  pIC50 = 5.21 ± 0.18, n = 4). 1-methylhistamine (pIC50 = 4.70 ± 0.07, n = 4), 3-methylhistamine (pIC50 = 4.87 ± 0.05, n = 5) and 4-methylhistamine (pIC50 = 4.94 ± 0.52, n = 4) also stimulated low potency responses. The H1 agonist 2-pyridylethylamine  stimulated a response, however the IC50 for this was greater than 100 μM.
Investigation of Gi and Gs coupling
All agonist responses were also examined following 24 hours pre-incubation with pertussis toxin (PTX). Agonist responses to all of the ligands mentioned above and listed in Table 1 were abolished by PTX (Figure 1b). None of the antagonist ligands used in this study stimulated any response either in the absence or following 24 hours pre-incubation with PTX.
Finally all ligands used in the study (agonists and antagonists) were examined in the absence of forskolin (with and without PTX pre-incubation) in order to look for any Gs-stimulatory responses than might otherwise have been masked by the presence of 4 μM forskolin. No responses were seen to any of the ligands (with the exception of impentamine, see below).
Determination of antagonist affinity
Measurements of antagonist affinity were them made in the presence of agonists of different efficacies, including full agonists, partial agonists and proxyfan (Figures 2 and 3; Table 2). Where possible, the response to each agonist was assessed in the presence of at three different concentrations of antagonists thus allowing a Schild plot to be constructed (Table 3). However, for many antagonist ligands, the affinity was relatively poor and hence antagonist affinity was assessed from parallel shifts in the presence of one or two concentrations of antagonist. The ability of the partial agonist VUF 5681 to inhibit the more efficacious agonists was also assessed (Table 3, Figure 4) however, here the affinity of VUF 5681 was calculated by the partial agonist method of Stephenson .
The ligands were then examined in the 3H-cAMP accumulation assay and again, the agonist actions of the ligands was clearly observed (Table 1). The antagonist affinity measurements of two of the antagonists, clobenpropit and thioperamide, were then examined in the 3H-cAMP accumulation assay (Figure 5, Table 4). Given that VUF 5681 and burimamide were more potent (i.e. left-shifted) in the 3H-cAMP accumulation assay, pKD values were also able to be determined when these ligands were the agonists (Table 4).
Impentamine stimulated a CRE-gene transcription response that was best described by a two-component concentration response curve pIC50 = 7.59 ± 0.05, n = 8 and pIC50 = 5.40 ± 0.05, n = 8, Figure 6a). When examined in the presence of any of the antagonists used in this study, only the first component was inhibited and this yielded a pKD value for each antagonist the same as those obtained in the presence of all other agonists (Table 2). When the impentamine response was examined following pre-incubation with PTX, the first component was abolished, and only the second component remained (pIC50 = 5.22 ± 0.22 n = 3, Figure 6b). Furthermore, this low potency component was seen in the absence of forskolin in CHO-H3-SPAP cells both with (pIC50 = 5.29 ± 0.17, n = 3) and without PTX pre-incubation (pIC50 = 5.18 ± 0.29, n = 3) and in CHO-SPAP cells (i.e. without the receptor) both with (pIC50 = 5.33 ± 0.08, n = 3) and without forskolin (pIC50 = 5.41 ± 0.06 n = 4, Figure 6c). Following 5 hours incubation with impentamine, CHO-H3-SPAP cells did not show any intracellular uptake of trypan blue. Finally, the 3H-cAMP accumulation response is best described by a one-component sigmoidal concentration response curve, the low potency component not being seen at all. Thus at high concentrations, impentamine appears to have been inhibiting the CRE-SPAP transcription or translation rather than appearing toxic to the cells, as they did not take up trypan blue following 5 hours incubation with impentamime and the 3H-cAMP accumulation response remained intact (i.e. no drop below basal that might have been expected with cell death). Taken together, this suggests that the first component of the impentamine response (Figure 6a) is due to partial agonism via the H3 receptor and the second component due to a non-specific non-receptor mediated inhibition of the CRE-SPAP response downstream from cAMP, and therefore unlike the two-component responses seen at either the β1-adrenoceptor (i.e. Figure 7 of ) or the β3-adrenoceptor (Figure 7 of ).
Investigation of the intrinsic activity of the H3-antagonists
Finally, as the histamine H3 receptor is known have constitutive activity (e.g. , the intrinsic efficacy of the antagonist ligands was examined. With the exception of the VUF 5681 (Table 1), none of the 11 other antagonist ligands stimulated a change in CRE-SPAP production in CHO-H3-SPAP cells. However, previous studies have however demonstrated that small changes may be more clearly seen in the 3H-cAMP accumulation assay due to the larger response window. All antagonist ligands were therefore examined in the 3Hc-AMP accumulation assay following 5 hours incubation with ligands in order to maximise any changes seen. In this assay, the IC50 values for the partial agonist VUF 5681 remained unchanged (pIC50 = 8.42 ± 0.05, n = 3). Inverse agonist responses were seen for conessine (pEC50 = 8.51 ± 0.20, 120 ± 1.5% basal, n = 4), thioperamide (pEC50 = 7.53 ± 0.11, 106.3 ± 2.6% basal, n = 4), ranitidine (pEC50 = 5.98 ± 0.21, 112.5 ± 2.0% basal, n = 4) and cimetidine (pEC50 = 6.62 ± 0.24, 110.7 ± 3.0% basal, n = 4; Figure 7). No responses were seen to zolatidine, dimethindine, iodophenpropit, clobenpropit, triprolidine, clemastine or chlorpheniramine (n = 4 for each ligand).
Lack of gene transcription responses in CHO-SPAP cells
The response to all ligand used in this study was examined in the parent CHO-SPAP cells (expressing the reporter but not the human H3 receptor). Full 7-point concentration response curves were constructed, in the presence and absence of 4 μM forskolin. No responses were seen in response to any ligand (except impentamine mentioned above), up to concentrations of 100 μM (or 10 μM in the case of zolatidine, conessine, iodophenpropit, clobenpropit, clemastine). A small decrease from maximum was seen only at the highest concentration (100 μM) of VUF 5681.
Several GPCRs have now been shown to exist in several different conformations, stablised by different agonists, that either couple to different G-proteins, signal via different pathways or to which ligands bind with different affinities . The histamine H3 receptor is a Gi-coupled receptor with a large range of ligands of varying efficacies thus making a detailed pharmacological study of the receptor possible. Several newer ligands have also been found for the H3 receptor and their structure is becoming increasingly diverse (e.g. conessine, a steroidal alkaloid from the stem bark of Funtumia elastica that has both antimicrobial activity against Plasmodium falciparim and H3 antagonist properties [40, 41]. The histamine H3 receptor has also been proven to exist in different agonist states or conformations. It is a constitutively active receptor and thus can exist in an inverse agonist state. In addition, proxyfan has been demonstrated to be a protean agonist . It stabilises a medium-efficacy state of the receptor which is distinct from the high efficacy histamine induced state . The purpose of this study was therefore to examine the pharmacology of the H3 receptor, and in particular antagonist affinity measurements made in the presence of agonists of different efficacies, including that state induced by proxyfan.
From the range of ligands investigated, many H3 agonists were identified. As well as the well-known ligands, others e.g. burimamide and impentamine were found to be agonists in keeping with a previous study in recombinant cells . In this study, in keeping with the previous study in recombinant cells , proxyfan was found to be a partial agonist when formation of cAMP was examined as well as down-stream CRE-gene transcription. VUF 8430 was reported to be a low potency full agonist at the H3 receptor  and was also found to be so in this study. In addition, and in contrast to other studies (e.g. ), other ligands were also found to have agonist properties e.g. the H2 agonists amthamine and dimaprit. VUF 5681 was previously reported to be a neutral antagonist of the histamine H3 receptor [43–45]. However, here it was found to have agonist activity in both the 3H-cAMP accumulation assay and the CRE-SPAP assay. As all of these responses did not occur in CRE-SPAP cells (without the H3 receptor) and their responses were sensitive to pre-incubation with pertussis toxin (PTX), they too were occurring via the histamine H3 receptor.
In view of the fact that the human histamine H3 receptor is known to be constitutively active , evidence for this was sought in terms of demonstrating inverse agonist action of the antagonist ligands. Given the low expression level of this cell line very little constitutive activity would be expected to be seen, and indeed this was the case. Only conessine, thioperamide, ranitidine and cimetidine were found to be inverse agonists in this relatively low expressing cell system. However, this nonetheless confirmed the constitute nature of this receptor. As there was relatively little constitutive activity, this should mean that a protean agonist would appear as a more efficacious agonist, as indeed proxyfan did. Because of this, antagonist affinity measurements from parallel shifts of an agonist response were more easily determined. It is interesting to note that several histamine ligands were found to have significant agonist activity in this cell system that has not been previously reported e.g. VUF 5681. It could therefore be that VUF 5681 is also a protean agonist and if examined in systems of different receptor expression and constitutive activity (as in ) this might be demonstrated. Proxyfan appears as a full agonist in this cell system and VUF 5681 as a partial agonist. If VUF 5681 is indeed a protean agonist, it stabilises a different, lower efficacy protean state of the receptor to that stabilised by proxyfan.
All agonists at the H3 receptor appeared more potent in the 3H-cAMP accumulation assay than in the CRE-gene transcription assay. This is in contrast to a recent study of the Gs-coupled human histamine H2 receptor (where all agonist responses were more potent in the CRE-gene transcription assay; ), but is similar to that seen in the Gi-coupled adenosine A1 receptor . Potencies between assays appear similar at the β1 and β3-adrenoceptor (except for weak partial agonists) but vary depending on the efficacy of the agonist at the β2-adrenoceptor. The reason for the change in potency between assays, that clearly varies with different GPCRs, remains unknown but may be related to different patterns of phosphorylation, internalisation and desensitisation that occur at different GPCRs [46, 47].
Another major conclusion that can be drawn from this study is that not all Gi-coupled receptors behave alike in a recombinant cell system. The Gi-coupled adenosine A1-receptor, expressed in the same CHO-reporter cell back ground as used in this study, clearly showed the receptor coupling to Gi and Gs-proteins . In this H3 study, all ligands were first assessed for their agonist activity in the presence and absence of forskolin, with and without PTX pre-incubation. Inhibitory responses were only ever seen. All of these responses were only seen in the presence of forskolin and all responses were abolished by pre-incubating the cells with PTX. The H3 receptor therefore did not demonstrate any Gs-coupled stimulatory CRE-gene transcription responses, even at high agonist concentrations, and thus has a different agonist receptor activation profile to the A1-adenosine receptor.
The affinity for the antagonists, as measured from parallel shifts of the agonist concentration response curve, remained constant at the human H3 receptor. Where values are available, the antagonist affinity values obtained here are similar to those previously published e.g. [26, 29]. This was also true for proxyfan stimulated responses. Conessine, a steroidal alkaloid and a natural product from the stem bark of Funtumia elastica, was a high affinity H3 inverse agonist and the pKD values for its antagonism of different H3-agonists obtained here were very similar to that reported by Cowart et al., . Thus, regardless of which competing agonist was used, the antagonist affinity of a given antagonist remained the same. Furthermore, the Schild plots, where possible, all had a slope of 1 confirming competitive antagonism. Again, where possible, this was true for the proxyfan stimulated responses. This was true even when examining the antagonism of partial agonist responses (e.g. burimamide, VUF 5681 and impentamine). This also held even when the antagonism of full agonists by a partial agonist (VUF 5681) was examined. Finally, the antagonist affinity values obtained were the same in the 3H-cAMP accumulation assay as the CRE-gene transcription assay. Therefore, the histamine H3 receptor is unlike any of the β-adrenoceptors in terms of simple antagonist affinity measurements. Antagonist affinity measurements remain constant at the H3 receptor, regardless of the competing agonist's efficacy, the cellular response measured, the time of incubation of agonist or the presence of a PDE inhibitor.
In conclusion, the human histamine H3 receptor is a Gi-coupled receptor that, in contrast to the human A1-receptor, has no evidence of coupling to Gs-proteins in this low receptor expressing recombinant cell system. Several ligands were identified as having agonist activity, including some ligands previously considered to be antagonists (e.g. VUF 5681, dimaprit). Given the low constitutive activity of this cell system, these ligands might yet turn out to be protean agonists. Conessine was shown to be a high affinity inverse agonist. Finally, the competitive nature of the antagonists was demonstrated and antagonist affinity measurements were constant for each antagonist, including at the proxyfan-induced medium-efficacy state of the H3 receptor, in contrast to all three subtypes of the β-adrenoceptors, but in keeping with the traditional pharmacological dogma.
Chinese hamster ovary
cyclic AMP response element
Dulbecco's modified Eagles medium/nutrient mix F12
G-protein coupled receptor
histamine trifluoromethyl toluidide
phosphate buffered saline
secreted placental alkaline phosphatise
- VUF 5681:
- VUF 8430:
2-[(aminoiminmethyl)amino]ethyl carbamimidothioic acid ester dihydrobromide.
Arunlakshana O, Schild HO: Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959, 14 (1): 48-58.
Ash ASF, Schild HO: Receptors mediating some actions of histamine. Br J Pharmacol Chemother. 1966, 27: 427-439.
Hill SJ: G protein-coupled receptors: past, present and future. Br J Pharmacol. 2006, 147: S27-S37. 10.1038/sj.bjp.0706455.
Black JW, Duncan WAM, Shanks RG: Comparison of some Properties of pronethalol and propranolol. Br J Pharmacol. 1965, 25: 577-591.
Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons ME: Definition and antagonism of histamine H2-receptors. Nature. 1972, 236: 385-390. 10.1038/236385a0.
Granneman JG: The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab. 2001, 280: E199-202.
Molenaar P: The 'state' of beta-adrenoceptors. Br J Pharmacol. 2003, 140: 1-2. 10.1038/sj.bjp.0705420.
Arch JR: Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine?. Br J Pharmacol. 2004, 143: 517-518. 10.1038/sj.bjp.0705991.
Pak MD, Fishman PH: Anomalous behaviour of CGP 12177A on beta 1-adrenergic receptors. J Recept Signal Transduction Res. 1996, 16: 1-23. 10.3109/10799899609039938.
Konkar AA, Zhu Z, Granneman JG: Aryloxypropanolamine and catecholamine ligand interactions with the β1-adrenergic receptor: evidence for interaction with distinct conformations of β1-adrenergic receptors. J Pharmacol Exp Ther. 2000, 294: 923-932.
Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of β-blockers for the two states of the β1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002, 135: 451-461. 10.1038/sj.bjp.0704450.
Baker JG, Hall IP, Hill SJ: Agonist actions of "β-blockers" provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor. Mol Pharmacol. 2003, 63: 1312-1321. 10.1124/mol.63.6.1312.
Baker JG: Sites of action of β-ligands at the human β1-adrenoceptor. J Pharmacol Exp Ther. 2005, 313: 1163-1171. 10.1124/jpet.104.082875.
Kaumann AJ, Preitner F, Sarsero D, Molenaar P, Revelli JP, Giacobino JP: (-)-CGP 12177 causes cardiostimulation and binds to cardiac putative beta 4-adrenoceptors in both wild-type and beta 3-adrenoceptor knockout mice. Mol Pharmacol. 1998, 53: 670-675.
Kaumann AJ, Engelhardt S, Hein L, Molenaar P, Lohse M: Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology. Naunyn Schmiedebergs Arch Pharmacol. 2001, 363: 87-93. 10.1007/s002100000336.
Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ: Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol. 2002, 62: 578-589. 10.1124/mol.62.3.578.
Cordeaux Y, Ijzerman AP, Hill SJ: Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation. Br J Pharmacol. 2004, 143: 705-714. 10.1038/sj.bjp.0705925.
Baker JG, Hill SJ: A comparison of the antagonist affinities for the Gi and Gs-coupled states of the human adenosine A1 receptor. J Pharmacol Exp Ther. 2007, 320: 218-228. 10.1124/jpet.106.113589.
Baker JG: Evidence for a secondary state of the human β3-adrenoceptor. Mol Pharmacol. 2005, 68: 1645-1655.
Baker JG, Hall IP, Hill SJ: Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: Differences between second messenger and reporter gene responses. Mol Pharmacol. 2003, 64: 679-688. 10.1124/mol.64.3.679.
Azzi M, Charest PG, Angers S, Rosseau G, Kohout T, Bouvier M, Pineryo G: Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA. 2003, 100: 11406-11. 10.1073/pnas.1936664100.
Baker JG, Hall IP, Hill SJ: Agonist and inverse agonist actions of "β-blockers" at the human β2-adrenoceptor provide evidence for agonist-directed signalling. Mol Pharmacol. 2003, 64: 1357-1369. 10.1124/mol.64.6.1357.
Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyadi L, Luttrell LM, Lefkowitz RJ: Independent β-arrestin 2 and G-protein-mediated pathways for angiotensin II activation of extracellular signal regulated kinase 1 and 2. Proc Natl Acad Sci USA. 2003, 100: 10782-10787. 10.1073/pnas.1834556100.
Sato M, Horinouchi T, Hutchinson DS, Evans BA, Summers RJ: Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists. Mol Pharmacol. 2007, 72: 1359-1368. 10.1124/mol.107.035337.
Baker JG: A study of antagonist affinities for the human histamine H2 receptor. British Journal of Pharmacology.
Parsons ME, Ganellin CR: Histamine and its receptors. Br J Pharmacol. 2006, 147: S127-35. 10.1038/sj.bjp.0706440.
Arrang JM, Garbarg M, Schwartz JC: Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature. 1983, 302: 832-837. 10.1038/302832a0.
Arrang J-M, Garbarg M, Lancelo J-C, Lecomte J-M, Pollard H, Robba M, Schunack W, Schwartz J-C: Highly potent and selective ligands for histamine H3-receptors. Nature. 1987, 327: 117-123. 10.1038/327117a0.
Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR, Erlander MG: Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol. 1999, 55: 1101-1107.
Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL: International Union of Pharmacology. XIII. Classification of Histamine Receptors. Pharmacol Rev. 1997, 49: 253-278.
Bongers G, Bakker RA, Leurs R: Molecular aspects of the histamine H3 receptor. Biochem Pharmacol. 2007, 73: 1195-1204. 10.1016/j.bcp.2007.01.008.
Kenakin T: Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 2001, 15: 598-611. 10.1096/fj.00-0438rev.
Gbahou F, Rouleau A, Morisset S, Parmentier R, Crochet S, Lin JS, Ligneau X, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, Arrang JM: Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci USA. 2003, 100: 11086-11091. 10.1073/pnas.1932276100.
Donaldson J, Brown AM, Hill SJ: Influence of rolipram on the cyclic-3',5'-adenosine monophosphate response to histamine and adenosine in slices of guinea-pig cerebral cortex. Biochem Pharmacol. 1988, 37: 715-723. 10.1016/0006-2952(88)90146-3.
Stephenson RP: A modification of receptor theory. Br J Pharmacol. 1956, 11: 5109-5116.
Qiu R, Melmon KL, Khan MM: Effects of histamine-trifluoromethyl-toluidide derivative (HTMT) on intracellular calcium in human lymphocytes. J Pharmacol Exp Ther. 1990, 253: 1245-52.
Martínez-Mir MI, Estañ L, Morales-Olivas FJ, Rubio E: Effect of histamine and histamine analogues on human isolated myometrial strips. Br J Pharmacol. 1992, 107: 528-531.
Wieland K, Bongers G, Yamamoto Y, Hashimoto T, Yamatodani A, Menge WM, Timmerman H, Lovenberg TW, Leurs R: Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther. 2001, 299: 908-14.
Baker JG, Hill SJ: Multiple GPCR conformations and signalling pathways: implications for antagonist affinity measurements. Trends Pharmacol Sci. 2007, 28: 274-381. 10.1016/j.tips.2007.06.011.
Zirihi GN, Grellier P, Guede-Guina F, Bodo B, Mambu L: Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf. Bioorg Med Chem Lett. 2005, 15: 2637-2640. 10.1016/j.bmcl.2005.03.021.
Cowart M, Sun M, Zhao C, Witte DG, Miller TR, Krueger KM, Browman K, Fox GB, Bennani YL, Esbenshade TA, Hancock AA: A new family of histamine H-3 receptor antagonists based on a natural product: discovery, SAR, and properties of the series. Inflammation Research. 2007, 56 (Suppl 1): S47-S48. 10.1007/s00011-006-0523-9.
Lim HD, Smits RA, Bakker RA, van Dam CM, de Esch IJ, Leurs R: Discovery of S-(2-guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist. J Med Chem. 2006, 49: 6650-6651. 10.1021/jm060880d.
Kitbunnadaj R, Zuiderveld OP, De Esch IJ, Vollinga RC, Bakker R, Lutz M, Spek AL, Cavoy E, Deltent MF, Menge WM, Timmerman H, Leurs R: Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists. J Med Chem. 2003, 46: 5445-5457. 10.1021/jm030905y.
Kitbunnadaj R, Zuiderveld OP, Christophe B, Hulscher S, Menge WM, Gelens E, Snip E, Bakker RA, Celanire S, Gillard M, Talaga P, Timmerman H, Leurs R: Identification of 4-(1H-imidazol-4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H(3) receptor agonist. J Med Chem. 2004, 47: 2414-7. 10.1021/jm049932u.
Moreno-Delgado D, Torrent A, Gomez-Ramirez J, de Esch I, Blanco I, Ortiz J: Constitutive activity of H-3 autoreceptors modulates histamine synthesis in rat brain through the cAMP/PKA pathway. Neuropharmacology. 2006, 51: 517-523. 10.1016/j.neuropharm.2006.04.010.
January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A, Barber R, Clark RB: β2-adrenergic receptor desensitization, internalization and phosphorylation in response to full and partial agonists. J Biol Chem. 1997, 272: 23871-23879. 10.1074/jbc.272.38.23871.
Clark RB, Knoll BJ, Barber R: Partial agonists and G-protein coupled receptor desensitization. Trends Pharmacol Sci. 1999, 20: 279-286. 10.1016/S0165-6147(99)01351-6.
JGB is a Wellcome Trust Clinician Scientist Fellow. She thanks Richard Proudman, Javeria Ahmad and Marleen Groenen for their technical assistance and Prof Steve Hill for useful discussions.
JGB conceived the study, carried out the experiments, data analysis and preparation of the manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Baker, J.G. Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells. BMC Pharmacol 8, 9 (2008). https://doi.org/10.1186/1471-2210-8-9
- Partial Agonist
- Inverse Agonist
- Full Agonist
- Concentration Response Curve